SEATTLE & IRVINE, Calif--(BUSINESS WIRE)--Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today announced that Ben Bergo, co-founder, and chief executive officer, will present at the JMP Securities Life Science Conference on May 15th, 2023, at the New York Hilton Midtown.
SEATTLE & IRVINE, Calif.--(BUSINESS WIRE)--Visus Therapeutics Inc., a clinical-stage pharmaceutical company, focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today reported positive topline results from its Phase 3 pivotal BRIO-I trial. BRIO-I met the pre-specified primary study endpoints agreed upon with the US-FDA and EMA/MHRA, demonstrating contribution of elements for the once-daily, fixed-dose combination, BRIMOCHOL PF, over both active comparators carbachol and brimonidine monotherapies. BRIMOCHOL PF demonstrated highly statistically significant improvements in near and distance binocular visual acuity at multiple timepoints over carbachol and brimonidine. Clinically and statistically significant reductions in pupil size were also observed out to 10 hours. BRIMOCHOL PF was well-tolerated with no treatment-related serious adverse events. Further details will be presented at upcoming meetings, including Eyecelerator during the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting taking place in San Diego, CA on May 4th.
SEATTLE & IRVINE, Calif.--(BUSINESS WIRE)--Visus Therapeutics Inc., a clinical stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye, today announced it will present new scientific data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held April 23-27, 2023 in New Orleans, Louisiana. The presentations will highlight new research findings on the Company’s alpha-crystallin aggregation inhibitor assets. Alpha-crystallin aggregation inhibitors are intended to restore elasticity and lens clarity, potentially reversing presbyopia and cataracts without the need for surgery.
Visus Therapeutics Appoints Ophthalmology Industry Expert Jehan Tamboowalla to Senior Vice President of Business Development and Marketing
Visus Therapeutics Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia
Visus Therapeutics to Attend TD Cowen’s 43rd Annual Health Care Conference
Visus Therapeutics Appoints World-Renowned Ophthalmologist, Eric D. Donnenfeld, M.D., to Board of Directors
SEATTLE--(BUSINESS WIRE)--Visus Therapeutics Inc., (“Visus”) a clinical stage biopharmaceutical company focused on developing multi-targeted treatments for the eye, today announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics, Inc. (“ViewPoint”). Founded in 2014, ViewPoint discovered and developed alpha-crystallin aggregation inhibitors as investigational non-surgical treatments to correct protein misfolding in the lens. Protein misfolding reduces lens elasticity and clarity leading to presbyopia and cataract, the leading causes of visual disability worldwide. Presbyopia is an inability to see near objects clearly, due to a loss of lens elasticity, that begins in the 40s and inevitably worsens with age. As protein misfolding worsens, cataracts, or clouding of the lens, may develop that can affect all vision-related activities. Alpha-crystallin aggregation inhibitors are intended to restore elasticity and lens clarity, potentially reversing presbyopia and cataracts without the need for surgery.
SEATTLE--(BUSINESS WIRE)--Visus Therapeutics, Inc. (“Visus”), a clinical stage biopharmaceutical company focused on treating complex and multifactorial conditions from the front to the back of the eye, today announced that Ben Bergo, co-founder and chief executive officer, will present at the Baird 2022 Global Healthcare Conference on September 13th, 2022, at the InterContinental New York Barclay hotel.
SEATTLE & HONG KONG--(BUSINESS WIRE)--Visus Therapeutics, Inc. (“Visus”), a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, and Zhaoke Ophthalmology Limited (“ZKO”), a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of treatments that address significant unmet medical needs, today announced an exclusive licensing agreement for the development and commercialization of BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and select Southeast Asian territories. BRIMOCHOL PF and Carbachol PF are investigational, preservative-free therapeutics designed to be long-acting, once-daily eye drops to correct for the loss of near vision associated with presbyopia.